A tripeptide
Technical Support & Resources

Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

DT-109

Item No. 41219

Technical Information
Formal Name
glycylglycyl-L-leucine
CAS Number
14857-82-0
Synonyms
  • Gly-Gly-L-Leu
Molecular Formula
C10H19N3O4
Formula Weight
Purity
≥95%
A solid
PBS (pH 7.2): Sparingly soluble: 1-10 mg/ml
SMILES
NCC(NCC(N[C@H](C(O)=O)CC(C)C)=O)=O
InChi Code
InChI=1S/C10H19N3O4/c1-6(2)3-7(10(16)17)13-9(15)5-12-8(14)4-11/h6-7H,3-5,11H2,1-2H3,(H,12,14)(H,13,15)(H,16,17)/t7-/m0/s1
InChi Key
XPJBQTCXPJNIFE-ZETCQYMHSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Wet ice in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

    Add

    Add

    Add

    Cayman Chemical
    Explore Obesity & Metabolic Disease Resources

    Discover high-quality research tools to investigate GLP-1 mechanisms and next-generation metabolic targets.

    OBESITY RESEARCH SOLUTIONS
    Product Description

    DT-109 is a tripeptide.1 It reduces blood glucose levels in an oral glucose tolerance test (OGTT) in mice. DT-109 (1 mg/g per day) reduces non-fasting blood glucose levels, serum total cholesterol and LDL levels, and adipocyte hypertrophy in Apo-/- mice. It reduces body fat mass, adipocyte hypertrophy, and hepatomegaly in a mouse model of diet-induced non-alcoholic steatohepatitis (NASH). DT-109 (500 mg/kg per day) also reverses hepatic steatosis and prevents the progression of fibrosis in a cynomolgus monkey model of NASH induced by a high-fat, high-fructose, and high-cholesterol diet.2

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Rom, O., Liu, Y., Liu, Z., et alGlycine-based treatment ameliorates NAFLD by modulating fatty acid oxidation, glutathione synthesis, and the gut microbiome. Sci. Transl. Med. 12(572), eaaz2841 (2020).

    2. Qu, P., Rom, O., Li, K., et alDT-109 ameliorates nonalcoholic steatohepatitis in nonhuman primates. Cell Metab. 35(5), 742-757 (2023).